Jun 10, 2025 (PRISM News via COMTEX) --
Quantum BioPharma Ltd. (QNTM) has expanded its commitment to digital assets by purchasing additional Bitcoin and cryptocurrencies, bringing its total investment in the sector to $5 million. The move reflects the Toronto-based biopharma company's belief in the potential of digital currencies to deliver shareholder returns and to serve as a hedge against fluctuations in the dollar.
Following board approval, Quantum BioPharma's new purchases position the company to accept cryptocurrency-based financing and transactions in the future. The company has emphasized that all crypto assets are held with a fully compliant custodian, ensuring that every transaction meets regulatory and financial reporting standards.
Management noted that while they see digital currencies as a strategic investment, the company will monitor market conditions closely and adjust their crypto holdings as appropriate.
Beyond its digital asset investments, Quantum BioPharma remains focused on advancing treatments for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse. Its flagship program, Lucid-MS, is designed to address myelin degradation in multiple sclerosis patients and is currently in preclinical development.
The post Quantum BioPharma Deepens Digital Holdings with Additional Bitcoin Purchase appeared first on PRISM MarketView.
COMTEX_466256692/2927/2025-06-10T15:02:46
